J. Ji

Attributable causes of cancer in China

Jianbo Wang, Y. Jiang, Hao Liang et al. · Annals of Oncology · 2012 · 122 citations · Full text

Medicine, Oncology, Preventive Medicine +10

Perioperative chemotherapy of oxaliplatin combined with S-1 (SOX) versus postoperative chemotherapy of SOX or oxaliplatin with capecitabine (XELOX) in locally advanced gastric adenocarcinoma with D2 gastrectomy: A randomized phase III trial (RESOLVE trial)

J. Ji, Lei Shen, Z. Li et al. · Annals of Oncology · 2019 · 42 citations · Full text

Medicine, Oncology, Surgery +15

Phase I trial of veliparib, (ABT-888), a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with doxorubicin and cyclophosphamide in breast cancer and other solid tumors.

Aimin Tan, D. Toppmeyer, Mark N. Stein et al. · Journal of Clinical Oncology · 2011 · 35 citations

Medicine, Oncology, Pharmacology +14

ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA

Yuqin Song, Keshu Zhou, D. Zou et al. · Hematological Oncology · 2019 · 18 citations

Medicine, Pharmacology, Pharmacotherapy +12

A phase I study of ABT-888 (A) in combination with metronomic cyclophosphamide (C) in adults with refractory solid tumors and lymphomas.

Shivaani Kummar, A. P. Chen, J. Ji et al. · Journal of Clinical Oncology · 2010 · 12 citations

Medicine, Oncology, Pharmacology +17